Login to Your Account

Unexpected Variability in Pain Intensity

Cadence Tumbles on Acetavance Miss in Postoperative Pain Study

By Jennifer Boggs

Monday, January 14, 2008
Shares of Cadence Pharmaceuticals Inc. plunged 61.7 percent after the company reported that its intravenous acetaminophen drug, Acetavance, failed to significantly reduce acute postoperative pain over placebo in a pivotal study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription